M.D. Anderson Cancer Center: Peritoneal Neoplasms trials

The registry lists 12 Peritoneal Neoplasms studies with M.D. Anderson Cancer Center as lead sponsor. 0 are open to participants now and 2 have results posted.

Early Phase 1 2Phase 1 6Phase 2 3No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal CancerCompletedNCT02891447Phase 2Results posted
• Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube CancerCompletedNCT00317772Phase 1/2Results posted
• Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative ChemotherapyCompletedNCT05083338
• Paclitaxel for the Treatment of Gastric or Gastroesophageal CancerActive, not recruitingNCT04220827Phase 1
• Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal CarcinomatosisCompletedNCT03508570Phase 1
• Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02316834Early Phase 1
• Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT01504126Early Phase 1
• Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal CancerWithdrawnNCT00634894Phase 2
• Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With CisplatinCompletedNCT00502177
• Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal CarcinomatosisCompletedNCT00491855Phase 1
• Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal CancerCompletedNCT00436657Phase 1
• PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube CancerCompletedNCT00059618Phase 1